☆ 4.7 Meeting Abstract

EFFICACY AND SAFETY OF RISANKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AFTER INADEQUATE RESPONSE OR INTOLERANCE TO DMARDs: 24-WEEK RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND KEEPsAKE 1 TRIAL

ANNALS OF THE RHEUMATIC DISEASES (2021)

Get Full Text
Add to Collection

Journal

ANNALS OF THE RHEUMATIC DISEASES
Volume 80, Issue -, Pages 1315-1316

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2021-eular.2678

Keywords

-

Categories

Rheumatology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.